Navigation Programs in Oncology" />NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Navigation Programs in Oncology" />
National Academies of Sciences, Engineering, and Medicine ; Health and Medicine Division ; Board on Health Care Services ; National Cancer Policy Forum .
Washington (DC): National Academies Press (US) ; 2018 May 24 . ISBN-13: 978-0-309-47454-2 ISBN-10: 0-309-47454-X Copyright 2018 by the National Academy of Sciences. All rights reserved. For more information, see the Bookshelf Copyright Notice.Delivering high-quality cancer care to all patients presents numerous challenges, including difficulties with care coordination and access. Patient navigation is a community-based service delivery intervention designed to promote access to timely diagnosis and treatment of cancer and other chronic diseases by eliminating barriers to care, and has often been proposed and implemented to address these challenges. However, unresolved questions include where patient navigation programs should be deployed, and which patients should be prioritized to receive navigation services when resources are limited.
To address these issues and facilitate discussion on how to improve navigation services for patients with cancer, the National Cancer Policy Forum of the National Academies of Sciences, Engineering, and Medicine held a workshop on November 13 and 14, 2017. At this workshop, a broad range of experts and stakeholders, including clinicians, navigators, researchers, and patients, explored which patients need navigation and who should serve as navigators, and the benefits of navigation and current gaps in the evidence base.
Rapporteurs: Sharyl J. Nass, Cyndi Trang, and Margie Patlak.
This activity was supported by Contract No. 200-2011-38807 (Task Order No. 0061) and Contract No. HHSN263201200074I (Task Order No. HHSN26300120) with the Centers for Disease Control and Prevention and the National Cancer Institute/National Institutes of Health, respectively, and by the American Association for Cancer Research, American Cancer Society, American College of Radiology, American Society of Clinical Oncology, American Society of Hematology, Association of American Cancer Institutes, Bristol-Myers Squibb, Cancer Support Community, CEO Roundtable on Cancer, Flatiron Health, Helsinn Therapeutics (U.S.), Inc., LIVESTRONG Foundation, Merck, National Comprehensive Cancer Network, Novartis Oncology, Oncology Nursing Society, and Pfizer Inc. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.
